IndraLab
Statements
sparser
"MN1 (Meningioma-1) is frequently over-expressed in AML patients and is associated with a poor prognosis. xref – xref However, in patients with inv(16), highest MN1 expression has been reported with favorable prognosis to current therapeutics. xref MN1 functions as a transcriptional regulator that co-operates with the nuclear receptors for retinoic acid (RAR) and vitamin D, by acting as co-activator or co-repressor, depending on the interacting partners. xref – xref In addition, MN1 is frequently over-expressed and occasionally fused to TEL as part of the rare MN1-TEL translocation. xref Mn1 is known to be co-operating partner of several oncogenic fusion genes (NUP98–HOXD13, xref CALM–AF10, xref MLL–AF9 xref and MLL–ENL) xref and mutated RUNX1, xref and as a common target of insertional mutagenesis in a hematopoietic stem cell (HSC) gene therapy trial, xref thereby promoting leukemogenesis."
sparser
"Wild type CALM (or PICALM) is involved in clathrin-mediated endocytosis, and an almost entire CALM protein, including its ENTH domain and the clathrin-binding domain, are present in the CALM-AF10 chimera, being fused to AF10 in which the first PHD finger (AF10 PHD1 ) is deleted."
sparser
"Gene MLL
Species
H, M H, M
Disease
Leukemia (AML, ALL, MLL) Acute myeloid leukemia (AML)
Genetic aberration/aberrant expression
>50 different MLL fusions MLL-PTD
References
Reviewed in Ref. [29] [72,73,135]
MLL2
H Hepatocellular carcinoma (HCC) M Acute myeloid leukemia (AML)
Hepatitis B virus integration into MLL2: HBx-MLL2 fusion NUP98-JARID1A
[136] [69]
MLL3 H Colorectal cancer
Intragenic mutations
[22]
DOT1L
H, M M H, M
Leukemia (AML, ALL) T-cell acute lymphoblastic leukemia (T-ALL) T-cell acute lymphoblastic leukemia (T-ALL)
MLL-AF10 fusion, MLL-AF4 fusion CALM-AF10 fusion SET-NUP214 fusion
[60,65] [61] [137]
EZH2
H H H H H H, M H H H
Bladder carcinoma Breast cancer Colorectal cancer (CRC) Gastric cancer Hepatocellular carcinoma (HCC) Lymphoma Melanoma Prostate cancer Various other cancers
Overexpression: reduced miR-101, gene amplification Overexpression: gene amplification Overexpression: gene amplification Overexpression Overexpression Overexpression: reduced miR-26a, gene amplification Overexpression Overexpression: reduced miR-101 mediated repression Overexpression
[13,17,99,138,139] [13,15,16,95] [13,140] [38] [141] [13,100,142,143] [95] [14,39,95] [13,95]
NSD1 NSD2
NSD3
H, M H H
H H H H H
H
Acute myeloid leukemia (AML) Myelodysplastic syndrome (MDS) Sotos syndrome
Glioblastoma multiform (GBM) Hepatocellular carcinoma (HCC) Leukemia Multiple myeloma (MM) Various other cancers
Acute myeloid leukemia (AML)
t(5;11)(q35;p15.5) translocation: NUP98–NSD1 fusion t(5;11)(q35;p15.5) translocation: NUP98–NSD1 fusion Intragenic mutations; 5q35 microdeletions
Overexpression Overexpression Overexpression t(4;14)(p16;q32): altered expression of FGFR3, NSD2 Overexpression
t(8;11)(p11.2;p15) translocation: NUP98–NSD3 fusion
[30,68,82] [31] [24,83,144,145]
[146] [147] [91] [33,84–86] [18]
[32]
SUV39H1/2 EHMT1
SETDB1
M
H H H
H
B-cell lymphoma
9q subtelomeric deletion syndrome Breast cancer Medulloblastoma
Huntington’s disease (HD)
Knockout mice
Haploinsufficiency of EHMT1 Intragenic mutations Downregulation
Overexpression
[46]
[27,148–150] [22] [151]
[152]
SMYD2 SMYD3
SMYD4
H
H H H
H H
Hepatocellular carcinoma (HCC)
Breast cancer Colorectal carcinoma (CRC) Hepatocellular carcinoma (HCC)
Breast cancer Medulloblastoma
Overexpression
Overexpression Overexpression Overexpression
Downregulation Downregulation
[26]
[153,154] [155] [155]
[156] [151]
PRDM1 PRDM2
PRDM5
PRDM12 PRDM14
H
H H M H H H, M H
H H H H
H
H
Lymphoma
Breast cancer Colorectal cancer (CRC) Diffuse B-cell lymphoma (DBCL) Gastric cancer Hepatocellular carcinoma (HCC) Lung cancer Neuroblastoma
Breast cancer Colorectal and gastric cancer Liver cancer Ovarian cancer cell lines
Chronic myeloid leukemia (CML)
Breast cancer
Mutations in PRDM1 gene; epigenetic silencing
Mutations in PRDM2 gene; promoter DNA methylation Mutations in PRDM2 gene Knockout mice Mutations in PRDM2 gene; promoter DNA methylation Downregulation; promoter DNA methylation Downregulation; knockout mice Downregulation
Downregulation; promoter DNA methylation Downregulation; promoter DNA methylation Downregulation; promoter DNA methylation Downregulation; promoter DNA methylation
9q microdeletions encompassing RRP4 and PRDM12
Overexpression
[21,40–42]
[20,34,157] [19,20] [158] [20,159] [36,160] [157,158] [157]
[37] [38] [37] [37]
[25,161]
[162]
PRMT1 CARM1 PRMT5
M H
H H
H
Acute myeloid leukemia (AML) Breast cancer cell lines
Breast cancer Prostate cancer
Lymphoma and leukemia
MLL-EEN fusion Overexpression
Overexpression Overexpression
Overexpression
[70] [163]
[164] [165,166]
[167,168]
M. Albert, K. Helin / Seminars in Cell & Developmental Biology 21 (2010) 209–220
213
several of the HMTs are important regulators of differentiation processes, one hypothesis is that misregulation of HMTs blocks normal differentiation and therefore contributes to tumor development."
sparser
"So far,
326 Gasparini et al.
TABLE I. Recurrent Balanced Rearrangements in Hematological Malignancies
Hemapoietic tumors
Lymphoid
Disease
Anaplastic large cell lymphoma
Burkitt’s lymphoma, B-cell ALL B-cell precursor acute lymphoid leukemia
Diffuse large B-cells lymphoma
Extranodal mucosa-associated lymphoid tissue Plasma cells myeloma Pre-T cell lymphoblastic leukemia, lymphoma
Acute promyelocytic leukemia Acute myeloid leukemia or CMML Acute myeloid leukemia
Affected gene
NPM-ALK TPM3-ALK TFG-ALK ATIC-ALK MSN-ALK CLTCL-ALK
MYC (relocation of IgH locus) MYC (relocation of IgK locus) MYC (relocation of IgL locus)
E2A-PBX1 E2A-HLF TEL-AML1 BCR-ABL MLL-AF4 IL3-IgH
BCL2-IgH BCL6-variant partners
BCL8-IgH FCGR2-Igl MUC1-IgH NFKB2-IgH
MALT1-API2 MALT1-IgH BCL10-IgH BCL10-Igk
FGFR3-IgH and MMSET MAF-IgH MAF-Igl
CCND1-IgH MUM/IRF4-IgH
MYC (Relocation to TCR a/d locus) LYL1 (Relocation to TCRB locus)
TAL2 (Relocation TCRb locus) SCL (Relocation to TCR a/d locus)
OLIG2 (Relocation to TCR a/d) LMO1(RBTN1) (Relocation to TCR a/d) LMO2 (RBTN2) (Relocation to TCR a/d)
HOX11 (Relocation to TCR a/d) HOX1 – 1L2 CALM-AF10
NUP98-RAP1GDS1
Myeloid
PML-RARa NPM-RARa PLZF-RARa
ETV6-variant partners
NUP98-variant partners MLL-variant partners AML1-ETO CBFB-MYH11 FUS-ERG CEV14-PDGFRB P300-MOZ MOZ-TIF2 MOZ-CBP DEK-NUP214 RBM15-MKL MLF1-NPM1 AML1-EVI1
Rearrangement
t(2;5)(q23;q35) t(1;2)(q25;p23) t(2;3)(p23;q21) inv(2)(p23q35) t(X;2)(q11 – 12;p23) t(2;17)(p23;q23)
t(8;14)(q24;q32) t(2;8)(p12;q24) t(8;22)(q24;q11)
t(1;19)(q23;p13) t(17;19)(q22;p13) t(12;21)(p12;q22) t(9;22)(q34;q11.2) t(4;11)(q21;q23) t(5;14)(q31;q32)
t(14;18)(q32;q21) t(3;v)(q27;v)
t(14;15)(q32;q11 – 13) t(1;22)(q22;q11) t(1;14)(q21;q32) t(10;14)(q24;q32)
t(11;18)(q21;q21) t(14;18)(q32;q21) t(1;14)(p22;q32)
t(1;2)(p22;p12)
t(4;14)(p16;q32) t(14;16)(q32;q23) t(16;22)(q23;q11) t(11;14)(q13;q32) t(6;14)(p25;q32)
t(8;14)(q24;q11) t(7;19)(q35;p13)
t(1;14)(p32;q11) t(14;21)(q11;q22) t(11;14)(p15;q11) t(11;14)(p13;q11) t(10;14)(q24;q11) t(5;14)(q35;q32) t(10;11)(p13;q21) t(4;11)(q21;p15)
t(15;17)(q21;q21) t(5;17)(q35;q21) t(11;17)(q23;q21)
t(12;v)(p13;v)
t(11;v)(p13;v) t(11;v)(q23;v) t(8;21)(q22;q22) inv(16)(p13q22) t(16;21)(p11;q22) t(5;14)(q33;q32) t(8;22)(q33;q32) inv(8)(p11q13)
t(6;9)(p23;q34) t(1;22)(p13;q13) t(3;5)(q25;q34) t(3;21)(q26;q22)
Chromosomal Alterations in Cancer Development
327
Fig. 2."
sparser
"It has been shown that PZP of AF10 engages the nucleosome through multivalent interactions with the entire H3 tail as well as DNA and that incorporation of functional PZP in leukemogenic CALM-AF10 fusions blocks the transforming activity in vitro and in vivo and abolishes CALM-AF10–driven leukemogenesis in vivo ( xref )."
sparser
"We identified SID7969543, an inhibitor of transcription factor Nuclear Receptor Subfamily 5 Group A Member 1 (NR5A1), as a novel selective candidate inhibitor against a subset of KMT2A-r and CALM-AF10 translocated leukemia cells, including cells derived from infants with KMT2A-r leukemia."
sparser
"This chimera consists of the C-terminal part of CALM (aa 400–648, CALM CT ), encompassing the TAD domain and NES, fused with AF10 OMLZ (aa 677–758) and represents the minimal fusion construct (CALM-AF10 MF ) that induces transformation to the same extent as the original CALM-AF10 fusion (Fig. xref ) xref ."
sparser
"We then transduced bone marrow-derived HSPCs with CALM-AF10 MF , CALM- PZP AF10 MF, or the MSCV-IRES-GFP (MIG) empty vector, purified transduced cells using a co-expressed fluorescence marker, and tested these cells in a methyl-cellulose-based semi-solid colony-forming unit (CFU) assay (Fig. xref )."
sparser
"Furthermore, undifferentiated colonies from CALM-AF10 MF transformed cells gave rise to the blast-like colonies in secondary and tertiary replating experiments, whereas the colonies from MIG vector or CALM- PZP AF10 MF transduced cells had no serial replating capacity (Fig. xref )."
sparser
"To further characterize the cytotoxic profile of the adenosine analog 2-Cl-ATP, the compound was evaluated in an expanded leukemia cell line panel comprising six additional KMT2A-r leukemia cell lines, including five derived from infants with KMT2A-r ALL and two CALM-AF10 translocated leukemias, which are KMT2A-wt but represent an aggressive leukemia subtype that shares underlying molecular etiological pathways with KMT2A-r leukemias, such as their dependency on DOT1L histone-lysine methyltransferase and an upregulation of HOXA cluster genes ( xref – xref )."
sparser
"To establish whether the inclusion of AF10 PZP can affect the in vivo leukemogenic activity of the CALM-AF10 translocation, we injected mice ( n = 5 mice per arm) with HSPCs transduced with either the MIG empty vector control, the CALM-AF10 MF fusion gene, or the CALM- PZP AF10 MF fusion gene (Fig. xref )."
sparser
"To determine the role of AF10 PZP in Hoxa gene expression, we transduced murine bone marrow-derived HSPCs with either the leukemia-associated CALM-AF10 fusion lacking the first 80 amino acids of AF10, including the first PHD finger (Fig. xref , second schematic), or a CALM-AF10 fusion (CALM- full AF10) which contains full-length AF10 (1–1027 amino acids), including the entire PZP domain, and measured Hoxa transcript levels by qRT-PCR."
sparser
"CALM-AF10 expression in murine bone marrow-derived HSPCs led to a substantial increase in Hoxa7 , Hoxa9 , Hoxa10 , and Meis1 levels compared to the levels of these genes in CALM- full AF10 expressing cells, indicating that the exclusion of AF10 PZP may be necessary for HOX/MEIS activation by the CALM-AF10 fusion protein (Fig. xref )."
sparser
"These results also help to explain the fact that AF10 PZP is disrupted in all CALM-AF10 fusions, as analysis of the TARGET pediatric AML dataset pointed out that most of the leukemia-associated breakpoints in the AF10 gene in pediatric leukemias are located in or right after AF10 PZP , and a few more breakpoints are located just upstream of AF10 OMLZ , but importantly, in all these fusions AF10 PZP is impaired or excluded (Fig. xref )."
sparser
"Our finding that SID7969543 also targets CALM-AF10 translocated leukemia cells, supports previous reports showing that KMT2A and CALM-AF10 translocations rely on common underlying leukemogenic pathways ( xref – xref ) and further emphasizes that both leukemia subtypes share common targetable vulnerabilities."
sparser
"This is in line with observations in our earlier studies that focused on large-scale chemical library screening and yielded novel candidate drug molecules with selectivity for KMT2A-r leukemia that were similarly cytotoxic against CALM-AF10 translocated leukemias ( xref , xref )."
sparser
"At the molecular level, PICALM/AF10 induces the overexpression of HOXA cluster genes (particularly Hoxa5 ) through aberrant methylation of Lys79 of Histone 3 via DOT1L recruitment. xref Hoxa5 overexpression is critical but not essential for CALM‐AF10 ‐mediated leukemogenesis. xref In the Caudell et al study, xref CALM‐AF10 transgenic mice showed Hoxa5 overexpression, although they did not develop acute leukemia."
sparser
"Furthermore, CALM- PZPmut AF10 MF fusion protein, harboring D43K/E179K mutations that disrupt binding to H3 tail, lost its ability to accumulate in the nucleus and was found primarily in the cytosol, confirming the importance of functional AF10 PZP for the nuclear pool of CALM-AF10 (Fig. xref , right panels)."
sparser
"In the absence of functional AF10 PZP within the leukemogenic fusion, CALM-AF10 can trap DOT1L at the Hoxa cluster, leading to the elevated local H3K79me2 level, constitutive activation of Hoxa genes, and a decrease in global H3K79me2 level due to the inability of the fusion to spread onto chromatin regions beyond the Hoxa loci (Fig. xref , top)."
sparser
"Furthermore, the genetic diversity of T-ALL also includes chromosomal rearrangements (CALM-AF10, MiLL1-ENL, and NUP214-AFBL1), loss of transcription factors (e.g., LEF1, WT1, RUNX1, ETV6, etc.), cell cycle inhibitors (e.g., CDKN2A, RB and CDKN1B) and oncogene gains (e.g., MYB) [ xref ]."
sparser
"The MOF inhibitor MG149 evidenced anti-leukemic activities of MLL-fused leukemia and other AML cell models that are associated with HOXA9 over-expression, such as the CALM-AF10 fusion model U937, but also the K562 cell model (BCR-ABL fusion) that does not express HOXA9 [ xref ], suggesting a more global epigenetic deregulation by MOF inhibitors that is not restricted to deregulated HOXA9 gene expression ( xref , point j ; xref )."
sparser
"Heterogeneous QKI expression has been shown in B-cell ALL, with QKI downregulation in pediatric subtypes of leukemia. xref MiR-155-dependent-QKI depletion has been implicated in inflammation in chronic lymphocytic leukemia. xref In T-ALL, QKI downregulation was reported in cases with high HOXA expression, carrying CALM-AF10 xref or KMT2A rearrangements. xref The QKI transcript displayed a highly heterogeneous level of expression in T-ALL (range, 0-15 transcripts per million) ( xref ), according to RNA-sequencing data in 25 pediatric patients xref representing five T-ALL molecular subtypes. xref Two groups of patients with normal (QKI_normal) and aberrantly low (QKI_low) QKI expression ( xref ) were defined by comparison with their normal counterparts, five thymocyte populations from two healthy donors including three CD34 + early maturation and two CD4 + CD8 + stages of the ab lineage. xref CircComPara2 12 identified 3,376 circRNA expressed in the T-ALL samples, with an average of five circular isoforms per gene, and 20 genes with at least 15 circular isoforms, including TASP1 and CASC15 , each with 30 circRNA."
sparser
"To first test our experimental system, we selected two monocytic PDX models that tolerated stable Cas9 expression and can be passaged for a limited time in vitro (PDX 16-01 with a CALM-AF10 fusion and PDX 17-14 with a MLL-AF10 fusion; see also xref and extended information xref )."
sparser
"The genetic abnormalities which are associated with good prognosis include chromosomal rearrangements involving TAL1 [t(1:14)], t(1:17), TALX1, HOXA (CALM-AF10), deletion CDKN2A/2B, mutation in NOTCH1 and those associated with poor prognosis include rearrangements of TLX3 and mutation involving EZH2 ( xref )."
sparser
"We have demonstrated that a CRM1-AF10 fusion protein phenocopies CALM-AF10 in its ability to bind and activate Hoxa and Meis1 genes and to induce leukemia, supporting a model in which CRM1 enables the tethering of CALM-AF10 to Hoxa and Meis1 effector genes, thereby recruiting the AF10/DOT1L transcriptional complex and causing leukemia."
sparser
"Similar to MLL-AF10, CALM-AF10 binds the regulatory region of HOXA genes and activates their transcription by recruiting the H3K79 histone methyltransferase DOT1L via an octapeptide-motif/leucine zipper (OM/LZ) domain within AF10 (also called Myeloid/Lymphoid or Mixed Lineage Leukemia, translocated to chromosome 10, MLLT10) [ xref ]."
sparser
"To determine whether CRM1 can substitute for CALM within the CALM-AF10 fusion, we examined the transforming properties of constructs encoding a chimeric CRM1-AF10 protein and a variant CRM1-AF10 fusion protein, CRM1Δ-AF10, that lacks the inhibitory 43 carboxy-terminal amino acid of CRM1; this construct mimics a fusion protein found in a leukemia patient ( xref ) [ xref ]."
sparser
"Cell 2005;121(2):167–78.
[61] Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 2006;8(9):1017–24.
[62] Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic."
sparser
"Additionally, UBE2J2 or UBE2K deletion increased venetoclax sensitivity even in the NOXA -null cells of multiple AML models, including another PDX-derived model cultured briefly in vitro (PDX16-01, with CALM-AF10 fusion, NF1 , PHF6 and TP53 mutations) (Fig. xref and Supplementary Fig, xref )."
sparser
"Other studies have shown that CD2 negativity correlated with the immature T-cell receptor and TCRγδ T-ALL lineages, which are associated with the occurrence of the CALM-AF10 fusion gene and the TLX3/HOX11L2 and MLL(KMT2A) gene rearrangements, considered to be prognostically unfavorable [ xref , xref , xref ]."
sparser
"WM1119 treatment reduced the presence of ENL and its cofactors at these target genes, accompanied by a reduction of the ChIP signal of RNAP2 Ser5-P. This suggests that WM1119 displaces ENL from the target promoters and impairs AEP-mediated transcriptional activation in CALM-AF10 leukemia cells."
sparser
"One of these other partners, PICALM::MLLT10 (originally called CALM::AF10 ) is generated by the t(10;11)(p12-13;q14-21) translocation, and has been rarely reported in patients with AML, acute lymphoblastic leukemia (ALL, especially T-phenotype), and acute undifferentiated leukemia. xref , xref The PICALM::MLLT10 fusion gene has been associated with high relapse rates and poor prognosis in adult AML, xref however, data are lacking in children with AML harboring this translocation."
sparser
"In contrast, the proliferation of normal human CD34 + cells was unaffected under the conditions where that of P31/FUJ cells was severely impaired (Fig. xref ), suggesting that the combined inhibition of MOZ/MORF KATs and DOT1L KMT selectively induces differentiation of CALM-AF10 leukemia cells."
sparser
"The small molecule CCI-006 was described as a novel inhibitor of mixed lineage leukemia (MLL)-rearranged, and CALM-AF10 translocated myeloid leukemia cells by targeting a metabolic vulnerability in a subset of low HIF1alpha/low MEIS1-expressing MLL-rearranged leukemia cells that present more glycolytic metabolic phenotype [ xref ]."
sparser
"This review highlights several gene mutations with a high frequency or a strong influence associated with favorable or unfavorable aspects of prognosis— NOTCH1 , FBXW7 , PTEN , LOH6q, CASP8AP2 , c-MYC , IL-7 , CALM-AF10 , and CDKN2A/B —and indicates that the actual incidence of mutations in T-ALL/LBL is much higher than currently recognized."
sparser
"Gene expression profiling has identified several potential prognostic indicators of inherited T-LBL, such as NOTCH1 , F-box and WD repeat domain-containing 7 ( FBXW7 ), phosphatase and tensin homolog ( PTEN ), loss of heterozygosity at chromosome 6q (LOH6q), CASP8-associated protein 2 ( CASP8AP2 ), c-MYC , interleukin-7 ( IL-7 ), CALM-AF10 , and cyclin-dependent kinase inhibitor 2A/B ( CDKN2A/B )."
sparser
"In addition, NUP98 fusion genes, including the NHD13 fusion, commonly activate HOXA/B genes ( xref ), which are associated with stem cell self-renewal signatures, and are downstream targets of a wide spectrum of mutations associated with leukemia, including MLL fusions, CALM-AF10 fusion, monosomy 7, and NPM1 truncation mutations( xref )."